(Circulation. 1997;96:1964-1969.)
© 1997 American Heart Association, Inc.
Articles |
Raloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed Rabbits
From the Center for Clinical and Basic Research, Ballerup, Denmark (N.H.B., J.H., I.B., C.C.), and Eli Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Ind (R.F.K.).
Background The beneficial effect of long-term hormone replacement therapy in terms of a decreased risk of cardiovascular disease is now generally accepted. Raloxifene, a selective estrogen receptor modulator, has demonstrated hypolipidemic properties while leaving the endometrium unstimulated.
Methods and Results For our study of the effects of raloxifene on atherosclerosis, 75 rabbits were ovariectomized and treated with either raloxifene, 17ß-estradiol, or placebo; 25 rabbits were sham operated and treated with placebo. After 45 weeks, the raloxifene group had two thirds of the aortic atherosclerosis, as evaluated by the cholesterol content of the proximal inner part of the aorta, found in the placebo group (placebo, 577±55.1 nmol/mg protein; raloxifene, 397±53.6 nmol/mg protein; P<.05); the estrogen group had one third of the aortic atherosclerosis in the placebo group (estrogen, 177±32.1 nmol/mg protein; P<.001). The sham-operated group (473±59.6 nmol/mg protein) was not significantly different from placebo. These effects were only partly explained by the changes in serum lipids and lipoproteins, and treatment with both estrogen and raloxifene independently predicted the response in aorta cholesterol. Because plasma levels of total raloxifene were low relative to clinical values in postmenopausal women, dose-response data for raloxifene are required.
Conclusions Our findings indicate that raloxifene hydrochloride has a potentially important antiatherogenic effect, analogous to that observed with estrogen in this model.
Key Words: atherosclerosis • lipids • prevention • estrogen • raloxifene
This article has been cited by other articles:
 |
|
 |
|
  I. Mercier, S. Mader, and A. Calderone Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism Cardiovasc Res, October 1, 2003; 59(4): 883 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Colacurci, D. Manzella, F. Fornaro, M. Carbonella, and G. Paolisso Endothelial Function and Menopause: Effects of Raloxifene Administration J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2135 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Hodgin and N. Maeda Minireview: Estrogen and Mouse Models of Atherosclerosis Endocrinology, December 1, 2002; 143(12): 4495 - 4501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Simoncini, A. R. Genazzani, and J. K. Liao Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene Circulation, March 19, 2002; 105(11): 1368 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Selzman, A. S. Turner, J. S. Gaynor, S. A. Miller, E. Monnet, and A. H. Harken Inhibition of Intimal Hyperplasia Using the Selective Estrogen Receptor Modulator Raloxifene Arch Surg, March 1, 2002; 137(3): 333 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saitta, D. Altavilla, D. Cucinotta, N. Morabito, N. Frisina, F. Corrado, R. D'Anna, A. Lasco, G. Squadrito, A. Gaudio, et al. Randomized, Double-Blind, Placebo-Controlled Study on Effects of Raloxifene and Hormone Replacement Therapy on Plasma NO Concentrations, Endothelin-1 Levels, and Endothelium-Dependent Vasodilation in Postmenopausal Women Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1512 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Herrington, B. E. Pusser, W. A. Riley, T. Y. Thuren, K. B. Brosnihan, E. A. Brinton, and D. B. MacLean Cardiovascular Effects of Droloxifene, a New Selective Estrogen Receptor Modulator, in Healthy Postmenopausal Women Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1606 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Miller Gender, Estrogen, and NOS : Cautions About Generalizations Circ. Res., November 26, 1999; 85(11): 979 - 981. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Figtree, Y.-q. Lu, C. M. Webb, and P. Collins Raloxifene Acutely Relaxes Rabbit Coronary Arteries In Vitro by an Estrogen Receptor–Dependent and Nitric Oxide–Dependent Mechanism Circulation, September 7, 1999; 100(10): 1095 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Brehme, B. Bruck, N. Gugel, M. Wehrmann, S. Hanke, G. Finking, F. W. Schmahl, and H. Hanke Aortic Plaque Size and Endometrial Response in Cholesterol-Fed Rabbits Treated With Estrogen Plus Continuous or Sequential Progestin Arterioscler Thromb Vasc Biol, August 1, 1999; 19(8): 1930 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Col, S. G. Pauker, R. J. Goldberg, M. H. Eckman, R. K. Orr, E. M. Ross, and J. B. Wong Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women Arch Intern Med, July 12, 1999; 159(13): 1458 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Mendelsohn and R. H. Karas The Protective Effects of Estrogen on the Cardiovascular System N. Engl. J. Med., June 10, 1999; 340(23): 1801 - 1811. [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan and M. Morrow Tamoxifen, Raloxifene, and the Prevention of Breast Cancer Endocr. Rev., June 1, 1999; 20(3): 253 - 278. [Abstract] [Full Text]
|
|
|
|
|
|
J. V. Pinkerton and R. Santen Alternatives to the Use of Estrogen in Postmenopausal Women Endocr. Rev., June 1, 1999; 20(3): 308 - 320. [Abstract] [Full Text]
|
|
|
|
|
|
P. Alexandersen, J. Haarbo, I. Byrjalsen, H. Lawaetz, and C. Christiansen Natural Androgens Inhibit Male Atherosclerosis : A Study in Castrated, Cholesterol-Fed Rabbits Circ. Res., April 16, 1999; 84(7): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holm, H. L. Andersen, G. Arroe, and S. Stender Gender Gap in Aortic Cholesterol Accumulation in Cholesterol-Clamped Rabbits : Role of the Endothelium and Mononuclear-Endothelial Cell Interaction Circulation, December 15, 1998; 98(24): 2731 - 2737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. U. Bryant, R. F. Kauffman, P. Iversen, D. A. Cox, B. H. Mitlak, and H. Heath III Comment on Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 3001a - 3002. [Full Text]
|
|
|
|
 |
|
 B. W. Walsh, L. H. Kuller, R. A. Wild, S. Paul, M. Farmer, J. B. Lawrence, A. S. Shah, and P. W. Anderson Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women JAMA, May 13, 1998; 279(18): 1445 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Delmas, N. H. Bjarnason, B. H. Mitlak, A.-C. Ravoux, A. S. Shah, W. J. Huster, M. Draper, and C. Christiansen Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women N. Engl. J. Med., December 4, 1997; 337(23): 1641 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Evans, A. Eckert, K. Lai, S. J. Adelman, and D. C. Harnish Reciprocal Antagonism Between Estrogen Receptor and NF-{kappa}B Activity In Vivo Circ. Res., October 26, 2001; 89(9): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, U. Laufs, D. Stamenkovic, W. Linz, J.-P. Stasch, K. Ahlbory, R. Rosen, M. Bohm, and G. Nickenig Raloxifene Improves Endothelial Dysfunction in Hypertension by Reduced Oxidative Stress and Enhanced Nitric Oxide Production Circulation, April 30, 2002; 105(17): 2083 - 2091. [Abstract] [Full Text] [PDF]
|
|